Ix Acquisition CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
IX Acquisition Corp. reports Q1 2026 results, showing a significant increase in net income driven by warrant revaluation, while continuing efforts to finalize its business combination with AERKOMM.
OTC.Pink
IX Acquisition Corp. reports a net loss of $770,658 for Q3 2025, extends its business combination deadline to October 2026, and continues efforts to close its merger with AERKOMM Inc. amidst delisting from Nasdaq.
OTC.Pink
IX Acquisition Corp. reports continued net losses, Nasdaq delisting, and further delays in its merger with AERKOMM Inc. for Q2 2025.
OTC.Pink
IX Acquisition Corp., a SPAC, reported a net income of $242,125 for Q1 2025, a significant improvement from the prior year's loss, as it continues efforts to finalize a business combination with AERKOMM Inc. despite recent delisting from Nasdaq.
OTC.Pink
IX Acquisition Corp. reported a net loss for Q3 2024, while continuing efforts to finalize a business combination and secure additional funding.
OTC.Pink
IX Acquisition Corp. filed an amended 10-Q to include previously omitted XBRL documents and clarify a note, while reaffirming its ongoing efforts to complete a business combination.
OTC.Pink
IX Acquisition Corp. reported a net loss of $1.3 million for the second quarter of 2024, primarily due to operating expenses and changes in the fair value of warrant liabilities, while continuing its efforts to complete a business combination.
OTC.Pink
IX Acquisition Corp. reported a net loss for Q1 2024 while progressing with a merger agreement and facing Nasdaq listing compliance issues.